{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T05:09:41Z","timestamp":1696050581173},"reference-count":65,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4169,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-5031.2004.00147.x","type":"journal-article","created":{"date-parts":[[2004,4,2]],"date-time":"2004-04-02T09:31:42Z","timestamp":1080898302000},"page":"277-284","source":"Crossref","is-referenced-by-count":4,"title":["Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs"],"prefix":"10.1155","volume":"58","author":[{"given":"D.F.","family":"O'Shaughnessy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2004,4,2]]},"reference":[{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2004.00147.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"176S","DOI":"10.1378\/chest.119.1_suppl.176S","article-title":"Antithrombotic therapy for venous thromboembolic disease","volume":"119","author":"Hyers","year":"2001","journal-title":"Chest"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1378\/chest.116.4.903","article-title":"High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism","volume":"116","author":"Girard","year":"1999","journal-title":"Chest"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"I22","DOI":"10.1161\/01.CIR.0000078464.82671.78","article-title":"Natural history of venous thromboembolism","volume":"107","author":"Kearon","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1164\/ajrccm.159.1.9803109","article-title":"Venous thromboembolism","volume":"159","author":"Hyers","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2004.00147.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1378\/chest.107.1_Supplement.3S","article-title":"Pulmonary embolism: epidemiology","volume":"107","author":"Giuntini","year":"1995","journal-title":"Chest"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/archinte.1991.00400050081016","article-title":"A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study","volume":"151","author":"Anderson","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archinte.1994.00420080053005","article-title":"The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly","volume":"154","author":"Kniffin","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2796.1992.tb00565.x","article-title":"A prospective study of the incidence of deep-vein thrombosis within a defined urban population","volume":"232","author":"Nordstrom","year":"1992","journal-title":"J Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0140-6736(98)07534-5","article-title":"Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)","volume":"353","author":"Goldhaber","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jama.279.6.458","article-title":"Risk of fatal pulmonary embolism in patients with treated venous thromboembolism","volume":"279","author":"Douketis","year":"1998","journal-title":"JAMA"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinte.160.6.761","article-title":"Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","article-title":"The long-term clinical course of acute deep venous thrombosis","volume":"125","author":"Prandoni","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1161\/01.CIR.99.10.1325","article-title":"Pulmonary embolism: one-year follow-up with echocardiography and five-year survival analysis","volume":"99","author":"Ribeiro","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/archinte.162.22.2521","article-title":"The uncertain role of thrombolytic therapy in the treatment of pulmonary embolism","volume":"162","author":"Dalen","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archinte.1995.00430060059007","article-title":"Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis","volume":"155","author":"Lensing","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0002-9343(97)89484-3","article-title":"Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis","volume":"100","author":"Siragusa","year":"1996","journal-title":"Am J Med"},{"issue":"Suppl. 7","key":"10.1111\/j.1368-5031.2004.00147.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003495-199600527-00006","article-title":"Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis","volume":"52","author":"Leizorovicz","year":"1996","journal-title":"Drugs"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archinte.160.2.181","article-title":"A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency","volume":"160","author":"Dolovich","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-130-10-199905180-00003","article-title":"Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials","volume":"130","author":"Gould","year":"1999","journal-title":"Ann Intern Med"},{"issue":"Issue 2","key":"10.1111\/j.1368-5031.2004.00147.x-BIB21|cit21","article-title":"Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism (Cochrane Review)","author":"Van Den Belt","year":"2003","journal-title":"The Cochrane Library."},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2004.00147.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin \u2212 Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJM198610303151801","article-title":"Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis","volume":"315","author":"Hull","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199211193272103","article-title":"Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis","volume":"327","author":"Brandjes","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.1992.00400200027006","article-title":"Optimal therapeutic level of heparin therapy in patients with venous thrombosis","volume":"152","author":"Hull","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1001\/archinte.1997.00440410049005","article-title":"The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence","volume":"157","author":"Hull","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.1997.00440430038005","article-title":"Relation between the time to achieve the lower limit of the aPTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis","volume":"157","author":"Hull","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/archinte.161.3.385","article-title":"Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin","volume":"161","author":"Bates","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJM200103013440902","article-title":"Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis","volume":"344","author":"Breddin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archinte.163.5.621","article-title":"Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis","volume":"163","author":"Hylek","year":"2003","journal-title":"Arch Intern Med"},{"issue":"Issue 2","key":"10.1111\/j.1368-5031.2004.00147.x-BIB31|cit31","article-title":"Once versus twice daily LMWH for the initial treatment of venous thromboembolism","author":"Van Dongen","year":"2003","journal-title":"The Cochrane Library."},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1055\/s-0037-1613337","article-title":"Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study","volume":"88","author":"Monreal","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-134-5-200103060-00013","article-title":"Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective","volume":"134","author":"Hirsh","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"V245","DOI":"10.1016\/S0049-3848(01)00325-5","article-title":"Unsolved issues in the treatment of pulmonary embolism","volume":"103","author":"Goldhaber","year":"2001","journal-title":"Thromb Res"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199603143341102","article-title":"Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home","volume":"334","author":"Koopman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199603143341101","article-title":"A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis","volume":"334","author":"Levine","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/000331979905001001","article-title":"Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis","volume":"50","author":"Belcaro","year":"1999","journal-title":"Angiology"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/archinte.160.12.1769","article-title":"Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study","volume":"160","author":"Boccalon","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/bmj.322.7296.1192","article-title":"Routine home treatment of deep vein thrombosis","volume":"322","author":"Eikelboom","year":"2001","journal-title":"BMJ"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7326\/0003-4819-130-10-199905180-00002","article-title":"Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis","volume":"130","author":"Gould","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0037-1613787","article-title":"Outpatient treatment of pulmonary embolism with dalteparin","volume":"83","author":"Kovacs","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1538-7836.2003.00005.x","article-title":"Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients","volume":"1","author":"Beer","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1055\/s-0037-1614065","article-title":"Predicting adverse outcome in patients with acute pulmonary embolism: a risk score","volume":"84","author":"Wicki","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2141.2002.03687.x","article-title":"Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin","volume":"118","author":"Lindhoff-Last","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00000658-199904000-00014","article-title":"Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes","volume":"229","author":"Heinzelmann","year":"1999","journal-title":"Ann Surg"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.1997.tb00321.x","article-title":"SR 90107\/Org 31540, a novel anti-factor Xa antithrombotic agent","volume":"15","author":"Herbert","year":"1997","journal-title":"Cardiovasc Drug Rev"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2004.00147.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers","volume":"41","author":"Donat","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2004.00147.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003088-200241002-00003","article-title":"Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs","volume":"41","author":"Lieu","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2004.00147.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003088-200241002-00004","article-title":"The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin","volume":"41","author":"Faaij","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2004.00147.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003088-200241002-00005","article-title":"Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers","volume":"41","author":"Ollier","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1111\/j.1368-5031.2004.00147.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00223-002-2091-5","article-title":"Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts","volume":"73","author":"Matziolis","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB52|cit52","doi-asserted-by":"crossref","unstructured":"Heinzelmann M Bosshart H. Fondaparinux lacks immunomodulatory effect of heparin. Am J Surg 2003 187 111 3","DOI":"10.1016\/j.amjsurg.2003.03.005"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2004.00147.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1378\/chest.119.1_suppl.132S","article-title":"Prevention of venous thromboembolism. Sixth ACCP Consensus Conference on antithrombotic therapy","volume":"119","author":"Geerts","year":"2001","journal-title":"Chest"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery. A meta-analysis of 4 randomized studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archinte.163.11.1337","article-title":"Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. A multicenter, randomized, placebo-controlled, double-blind study","volume":"163","author":"Eriksson","year":"2003","journal-title":"Arch Intern Med"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2004.00147.x-BIB60|cit60","first-page":"336","article-title":"The MATISSE-DVT trial, a randomized, double-blind study comparing once-daily fondaparinux (Arixtra\u00ae) with the low-molecular-weight heparin enoxaparin, twice daily, in the initial treatment of symptomatic deep-vein thrombosis","volume":"1","author":"The Matisse Investigators","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2004.00147.x-BIB61|cit61","first-page":"336","article-title":"The MATISSE-PE trial, a multicenter, randomized, open study comparing once-daily fondaparinux (Arixtra\u00ae) with adjusted-dose intravenous unfractionated heparin in the initial treatment of acute symptomatic pulmonary embolism","volume":"1","author":"The Matisse Investigators.","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1046\/j.1538-7836.2003.00396.x","article-title":"The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopaedic surgery","volume":"1","author":"Gordois","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB63|cit63","first-page":"102","article-title":"Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study","author":"Francis","year":"2003","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2004.00147.x-BIB64|cit64","first-page":"404","article-title":"Absence of transaminase increase after four-week administration of fondaparinux (Arixtra\u00ae), a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study","volume":"1","author":"Lassen","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1368-5031.2004.00147.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMe038152","article-title":"Treating thrombosis in the 21st century","volume":"349","author":"Shapiro","year":"2003","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-5031.2004.00147.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-5031.2004.00147.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:20Z","timestamp":1643349860000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-5031.2004.00147.x"}},"subtitle":["Current Perspectives On The Treatment Of Venous Thromboembolism"],"short-title":[],"issued":{"date-parts":[[2004,4,2]]},"references-count":65,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1111\/j.1368-5031.2004.00147.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4,2]]}}}